UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Link zum Volltext

Verfügbarkeit prüfen

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Link zum Volltext

Verfügbarkeit prüfen

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Link zum Volltext

Verfügbarkeit prüfen

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.883-892

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, obesity & metabolism, 2015-07, Vol.17 (7), p.630-638

2015

Link zum Volltext

Verfügbarkeit prüfen

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.891-899

Davis, T. M. E.

2014

Link zum Volltext

Verfügbarkeit prüfen

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.523-532

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1513-1520

2017

Link zum Volltext

Verfügbarkeit prüfen

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.567-576

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.487-494

2015

Link zum Volltext

Verfügbarkeit prüfen

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1253-1262

2016

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Link zum Volltext

Verfügbarkeit prüfen

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.850-858

2011

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin efficacy

Diabetes, obesity & metabolism, 2010-08, Vol.12 (8), p.734-734

Valiquette, G.

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Diabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.443-450

2014

Link zum Volltext

Verfügbarkeit prüfen

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.61-71

2022

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study

Diabetes, obesity & metabolism, 2024-05, Vol.26 (5), p.1670-1677

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

KollektionMEDLINE

Zeitschrift / SerieDiabetes, Obesity & Metabolism

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Adamantane - Analogs & Derivatives
(20)
Diabetes Mellitus, Type 2 - Drug Therapy
(20)
Endocrinology & Metabolism
(20)
Humans
(20)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Adamantane - Therapeutic Use
(17)
Dipeptides - Therapeutic Use
(17)
Diabetes
(15)
Female
(14)
Male
(14)
Treatment Outcome
(14)
Diabetes Mellitus
(13)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(13)
Middle Aged
(13)
Double-Blind Method
(12)
Aged
(11)
Type 2 Diabetes
(11)
Adult
(9)
Hemoglobin
(9)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Diabetes, Obesity And Metabolism
(1)

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Baseline differences in the SAVOR trial

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Saxagliptin efficacy

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study

Aktive Filter

Suchergebnisse filtern